FDA Grants Priority Review for Pfizer’s Prostate Cancer Combination Therapy
Event summary
- FDA accepted Pfizer’s sNDA for TALZENNA plus XTANDI in HRR gene-altered mCSPC under Priority Review.
- PDUFA action date set for Q4 2026; if approved, expands use to earlier-stage prostate cancer.
- Phase 3 TALAPRO-3 trial showed 52% reduction in progression/death risk vs. placebo plus XTANDI.
- Combination already approved in >60 countries for mCRPC; EMA review ongoing.
The big picture
This marks Pfizer’s push to dominate prostate cancer treatment by targeting earlier disease stages with biomarker-selected combinations. The strategy aligns with broader oncology trends favoring precision medicine and combination therapies. Success here could extend TALZENNA/XTANDI’s $1B+ franchise potential while reinforcing Pfizer’s leadership in genomic-driven oncology.
What we're watching
- Regulatory Timing
- Whether the FDA approval will materialize by Q4 2026 as projected.
- Commercial Upside
- The pace at which Pfizer can expand use of this combination into earlier-stage prostate cancer if approved.
- Competitive Dynamics
- How this moves the needle against rivals like AstraZeneca’s Lynparza in PARP inhibitor space.
Related topics